



(51) International Patent Classification:

C07K 14/52 (2006.01) A61P 31/12 (2006.01)
C07K 14/475 (2006.01) A61P 31/18 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2020/039143

(22) International Filing Date:

23 June 2020 (23.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/866,584 25 June 2019 (25.06.2019) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).(72) Inventors: AMBROGELLY, Alexandre; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, California
94404 (US). BACA, Manuel; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
CARR, Brian A.; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404 (US). CHU, Hon Man
Hamlet; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). HUNG, Magdeleine S.; c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, Cali-
fornia 94404 (US). KANWAR, Manu; c/o Gilead Sciences,

Inc., 333 Lakeside Drive, Foster City, California 94404
(US). KUHNE, Michelle R.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). RE-
HDER, Douglas S.; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404 (US). SCHENAUER,
Matthew R.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, California 94404 (US). WILSON, Nicholas S.;
c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
California 94404 (US).

(74) Agent: BRINKER, Achim et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: FLT3L-FC FUSION PROTEINS AND METHODS OF USE

Comparison of recombinant
human FLT3L-Ligand formats
compared to comparator 1




Fig. 1

(57) Abstract: Provided are FLT3L-Fc fusion proteins, polynucleotides encoding such fusion proteins, expression cassettes, vectors, cells and kits comprising such fusion proteins, and methods of using.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*